Clinical trials: Inhibition, Psychological

Peripheral Nerve Sheath Tumor

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

• Active, not recruiting
• Age: 12 to 99 years
• Phase 2
• Results posted

This phase 2, open label, single arm study will investigate the use of tazemetostat in patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath tumors.

Trial name

NCT04917042

Testing

Tazemetostat

Where

United States

Volunteers

10 people

Sponsor

University of Florida